Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure

Table 1

Baseline demographic, clinical, and laboratory characteristics of HB-ACLF survivors and nonsurvivors in the training set.

	Total	Survivors	Nonsurvivors
Number	60	45	15
Age (yr)	44 (25-67)	42 (25-63)	51 (31-67)	≤0.001
Sex, male (, %)	53 (88.3)	40 (88.9)	13 (86.7)	0.816
HBeAg positive (, %)	39 (65.0)	28 (62.2)	11 (73.3)	0.435
HBV-DNA (lg copies/ml)	6.93 (2.97-9.02)	7.08 (2.97-9.02)	6.66 (3.63-9.00)	0.335
Serum bilirubin (mg/dl)	18.88 (7.39-36.68)	18.58 (8.12-36.68)	21.43 (7.39-28.40)	0.242
Serum albumin (g/l)	29 (18-38)	30 (18-38)	27 (23-33)	0.023
ALT (U/ml)	644.5 (64-3291)	515 (64-3291)	677.8 (206-1227)	0.389
AST (U/ml)	365.3 (45-2265)	317 (45-2265)	590.9 (126-1231)	0.099
INR	2.21 (1.66-4.60)	2.14 (1.66-3.44)	2.66 (1.73-4.60)	0.043
Baseline sCr (mg/dl)	65 (32.83-108)	64 (36-108)	70 (32.83-99)	0.191
Leukocyte count (10^9/l)	6.64 (2.69-13.59)	6.65 (2.69-13.59)	6.28 (3.63-12.37)	0.959
Platelet count (10^9/l)	109 (44-309)	109 (44-309)	105 (49-166)	0.585
MELD score	23 (13-35)	23 (13-29)	25 (20-35)	0.029
CLIF-C OF	9 (7-12)	9 (7-12)	10 (8-12)	0.001
CRP (ng/ml)	6.89 (1.25-67.58)	6.04 (1.31-67.58)	12.71 (1.25-29.50)	≤0.001
PCT (ng/ml)	0.45 (0.12-5.90)	0.41 (0.14-5.90)	0.82 (0.12-2.0)	≤0.001
SuPAR (ng/ml)	12.61 (2.25-68.44)	10.61 (2.29-68.44)	25.68 (2.25-42.61)	≤0.001
Complications (, %)
Infection	45 (75)	31 (68.9)	14 (93.3)	0.086
Gastrointestinal bleeding	5 (8.3)	0 (0)	5 (33.3)	0.001
Hepatic encephalopathy	18 (30)	9 (20)	9 (60)	0.016
HRS	6 (10)	0 (0)	6 (40)	≤0.001

: number; yr: year; sCr: serum creatinine; MELD: model for end-stage liver disease; CLIF-C OF: chronic liver failure consortium organ failure; CRP: C-reactive protein; PCT: procalcitonin; HRS: hepatorenal syndrome.